Screener
Allogene Therapeutics ALLO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $32,003 | $50,200 |
| General and administrative | 14,089 | 14,991 |
| Total operating expenses | 46,092 | 65,191 |
| Loss from operations | (46,092) | (65,191) |
| Other income (expenses), net: | ||
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
| Other income (expenses), net | 212 | 92 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's operating income?
- Allogene Therapeutics (ALLO) reported operating income of -$46.09M in Q1 2026.
- How has Allogene Therapeutics's operating income changed year-over-year?
- Allogene Therapeutics's operating income increased by 29.3% year-over-year, from -$65.19M to -$46.09M.
- What is the long-term trend for Allogene Therapeutics's operating income?
- Over 4 years (2021 to 2025), Allogene Therapeutics's operating income has grown at a 3.6% compound annual growth rate (CAGR), from -$181.9M to -$209.32M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Allogene Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude